Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Tafenoquine 50 mg	0
Overall Study	STARTED	Tafenoquine 100 mg	14
Overall Study	STARTED	Tafenoquine 150 mg	5
Overall Study	STARTED	Tafenoquine 200 mg	22
Overall Study	STARTED	Tafenoquine 300 mg	19
Overall Study	COMPLETED	Tafenoquine 50 mg	0
Overall Study	COMPLETED	Tafenoquine 100 mg	14
Overall Study	COMPLETED	Tafenoquine 150 mg	5
Overall Study	COMPLETED	Tafenoquine 200 mg	22
Overall Study	COMPLETED	Tafenoquine 300 mg	19
Overall Study	NOT COMPLETED	Tafenoquine 50 mg	0
Overall Study	NOT COMPLETED	Tafenoquine 100 mg	0
Overall Study	NOT COMPLETED	Tafenoquine 150 mg	0
Overall Study	NOT COMPLETED	Tafenoquine 200 mg	0
Overall Study	NOT COMPLETED	Tafenoquine 300 mg	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02563496/flow